You are hereJanuary 3, 2020
MSC Therapy for Osteogenesis Imperfecta Treatment
A new STEM CELLS article from the lab of Ivo Kalajzic (UConn Health, Farmington, Connecticut, USA) recently presented a novel translational approach for the treatment of osteogenesis imperfecta (OI). While previous attempts to treat OI using stem cells via systemic transplantation failed, Sinder et al. show positive long‐term effects on bone microarchitecture and biomechanics after the direct intra‐bone transplantation of bone marrow‐derived mesenchymal stem cells (MSCs). Using fluorescent genetic markers, the authors tracked donor stem cells and their ability to differentiate into osteoblasts and osteocytes, finding that engraftment persisted for at least six months following transplantation, and cells show stem cell potential based on engraftment following secondary transplantation.